Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation

27 Dec 2016

Abstract excerpt

Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of the complement protein C5 and shows remarkable clinical benefits in certain complement-mediated diseases. However, several reports suggest that activation of C5 is not always completely suppressed in patients even under excess of eculizumab over C5, indicating that residual C5 activity may derogate the drug's therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Platelet Disorders and Treatments
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28028023
DOI: 10.1182/blood-2016-08-732800

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activationPMID 28028023Read ↗

Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.Semantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiationSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Eculizumab fails to inhibit generation of C5a in vivoSemantic proximity Read ↗

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.Semantic proximity Read ↗

Modulation of complement membrane attack by local C7 synthesisSemantic proximity Read ↗

Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.